Phenothiazines Boost Macrophage Antibacterial Activity via ROS and Autophagy

Study Background and Research Question

Bacterial infections continue to pose a critical threat to global health, causing more than ten million deaths annually. The mounting challenge of antimicrobial resistance (AMR) has rendered many traditional antibiotics less effective, particularly against intracellular pathogens such as Salmonella enterica serovar Typhimurium, Shigella flexneri, Staphylococcus aureus, and Listeria monocytogenes [source_type: paper][source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full]. These bacteria evade antibiotic action by residing within host cells, complicating eradication and treatment. As a result, there is a pressing need for therapeutic approaches that harness the host’s own immune defenses, particularly those mediated by macrophages—the frontline innate immune cells responsible for engulfing and destroying pathogens through processes such as autophagy and reactive oxygen species (ROS) production.

Key Innovation from the Reference Study

The open-access study by Qiu et al. (2025) makes a significant contribution by providing mechanistic insight into how phenothiazines, a class of antipsychotic compounds, can act as host-acting compounds (HACs) to boost macrophage antibacterial activity. Rather than directly targeting bacteria, phenothiazines were shown to enhance the innate immune response by inducing autophagy and increasing ROS production within macrophages. This mechanism represents a shift from classical antibiotic strategies to host-directed therapies (HDTs), which are less likely to drive resistance and may leave the commensal microbiota undisturbed [source_type: paper][source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full].

Methods and Experimental Design Insights

The investigators employed a comprehensive approach to dissect the effects of phenothiazines on macrophage function:

• Cellular assays: Macrophages were treated with several phenothiazines, and their antibacterial capacity was assessed by measuring bacterial survival following infection with intracellular pathogens.
• Lysosomal and autophagic flux measurements: Changes in lysosomal activity, autophagy marker expression, and autophagosome formation were quantified to evaluate the activation of host defense pathways.
• ROS detection: The accumulation of ROS within macrophages was measured using fluorescence-based probes.
• Pharmacological inhibition: To clarify the mechanistic role of autophagy and ROS, macrophages were co-treated with specific autophagy inhibitors or ROS scavengers, and subsequent antibacterial effects were assessed.
• In vivo validation: The efficacy of phenothiazines was further examined in murine models of S. Typhimurium infection, with outcomes including organ lesion scoring and inflammatory marker analysis.

Collectively, this multifaceted approach allowed the authors to pinpoint the necessity of both autophagy and ROS generation in mediating the observed antibacterial effect.

Protocol Parameters

• assay | phenothiazine treatment (concentration not specified) | activation of macrophage autophagy and ROS | to enhance antibacterial defense | paper [source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full]
• assay | use of autophagy inhibitors or ROS scavengers | mechanistic dissection | to demonstrate dependence of antibacterial effect on these pathways | paper [source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full]
• assay | in vivo dosing with perphenazine | reduction in organ lesions in S. Typhimurium-infected mice | to validate translational relevance | paper [source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full]
• assay | dopamine D2 receptor inhibitor (e.g., Trifluoperazine 2HCl) at 1–10 μM | neuropharmacology and immunomodulation studies | common working range in dopaminergic signaling pathway modulation | workflow_recommendation

Core Findings and Why They Matter

The study’s primary findings can be summarized as follows:

• Phenothiazines increase macrophage antibacterial activity by inducing autophagy and boosting ROS accumulation. These effects were observed across several intracellular bacterial pathogens.
• Autophagy and ROS are essential mediators: The antibacterial effect was markedly diminished when either autophagy or ROS was pharmacologically inhibited, confirming their central roles.
• In vivo validation: Treatment with perphenazine led to reductions in organ lesions and inflammation in a murine model of S. Typhimurium infection, supporting the translational potential of this approach.

These results suggest that phenothiazines, including those with established activity as dopamine D2 receptor inhibitors, could serve as lead compounds for host-directed antibacterial strategies. This approach may circumvent some limitations of traditional antibiotics, such as the promotion of resistance and disruption of the gut microbiota [source_type: paper][source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full].

Comparison with Existing Internal Articles

The connection between phenothiazines’ neuropharmacological properties and their immunomodulatory effects has been explored in several internal resources:

• The article “Trifluoperazine 2HCl: Mechanistic Insights and Strategic ...” discusses how Trifluoperazine 2HCl, a dopamine D2 receptor inhibitor, bridges neuropharmacology and immunology through its impact on dopamine receptor signaling and host-pathogen interactions. The reference study provides direct mechanistic evidence supporting these dual-domain applications [source_type: internal_article][source_link: https://epoxomicin.com/index.php?g=Wap&m=Article&a=detail&id=219].
• “Trifluoperazine 2HCl: Expanding Frontiers in Dopamine Rec...” highlights the compound’s applications in both dopaminergic signaling research and host-directed antibacterial strategies. The current paper’s findings reinforce the relevance of dopamine receptor antagonists in modulating macrophage function and immune defense [source_type: internal_article][source_link: https://pfi-2.com/index.php?g=Wap&m=Article&a=detail&id=218].
• For laboratory application guidance, “Trifluoperazine 2HCl (SKU B1397): Scenario-Driven Solutio...” provides best practices for assay reproducibility and workflow optimization using this compound in both neuropharmacology and immunology settings [source_type: internal_article][source_link: https://nimorazolecatalog.com/index.php?g=Wap&m=Article&a=detail&id=132].

Thus, the reference study supplies direct experimental validation for the translational hypotheses previously discussed in these internal analyses, particularly around the intersection of dopaminergic signaling pathway modulation and host antibacterial responses.

Why this cross-domain matters, maturity, and limitations

The translational bridge from neuropharmacology to immunology is supported by mechanistic evidence that dopamine D2 receptor antagonists—such as Trifluoperazine 2HCl—can modulate macrophage host defense, in addition to their established effects on dopaminergic signaling. While this approach is promising for host-directed antibacterial therapy, most evidence remains preclinical. The maturity of this strategy for clinical translation is moderate, as further studies are required to determine safety, optimal dosing, and efficacy in humans. Limitations include potential off-target effects, dose-dependent toxicity, and the need for selective activation of immune pathways without triggering detrimental inflammation [source_type: paper][source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full].

Limitations and Transferability

Despite the robust mechanistic evidence, several limitations merit consideration:

• Translatability: Most experiments were performed in vitro or in murine models; extrapolation to human clinical settings will require additional validation.
• Specificity: Phenothiazines can have diverse biological effects, and unintended modulation of other signaling pathways or cell types is possible.
• Dosing and safety: The pharmacological window for immunomodulation without neuropsychiatric or systemic side effects remains to be defined [source_type: paper][source_link: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1712724/full].

Researchers aiming to leverage these findings should consider parallel controls and dose optimization when designing experiments with dopamine receptor antagonists in immunological assays.

Research Support Resources

For laboratories seeking to replicate or extend these findings, Trifluoperazine 2HCl (SKU B1397) is available as a research-grade dopamine D2 receptor inhibitor. This compound offers validated solubility and stability profiles suitable for both neuropharmacology assay development and studies of macrophage-mediated antibacterial activity [source_type: product_spec][source_link: https://www.apexbt.com/trifluoperazine-2hcl.html]. For protocol optimization and best practices in dopaminergic pathway and immune modulation workflows, relevant scenario-driven articles and APExBIO product specifications may offer additional practical guidance.